Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B
暂无分享,去创建一个
H. Kuo | Jyh-Jou Chen | P. Cheng | Yen-Cheng Chiu | Pei‐Lun Lee | Hung-Chih Chiu | Shih-Chieh Chien | Ming-Lung Yu | I-Cher Feng | Pei-Jer Chen | Chun-Jen Liu
[1] S. Ahn,et al. Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B , 2022, Liver international : official journal of the International Association for the Study of the Liver.
[2] N. Sakamoto,et al. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B , 2022, PloS one.
[3] N. Park,et al. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis , 2021, Clinical and molecular hepatology.
[4] P. Mallon,et al. Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides , 2021, Open forum infectious diseases.
[5] Ming‐Lung Yu,et al. Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide☆. , 2021, Journal of the Formosan Medical Association = Taiwan yi zhi.
[6] Yoshiyuki Suzuki,et al. Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs , 2021, Journal of Gastroenterology.
[7] Guo-feng Chen,et al. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low‐level viraemia , 2021, Liver international : official journal of the International Association for the Study of the Liver.
[8] A. Tanaka. JSH Guidelines for the Management of Hepatitis B Virus Infection: 2019 Update. , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.
[9] L. Taramasso,et al. The switch from TDF to TAF determines weight gain in patients on rilpivirine-based regimen. , 2020, AIDS.
[10] J. Kao,et al. Systematic review: chronic viral hepatitis and metabolic derangement , 2019, Alimentary pharmacology & therapeutics.
[11] H. Stellbrink,et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] A. Vos,et al. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. , 2019, The New England journal of medicine.
[13] G. Z. Rocha,et al. Insulin Resistance in HIV-Patients: Causes and Consequences , 2018, Front. Endocrinol..
[14] S. Alavian,et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.
[15] S. Kottilil,et al. Chronic Hepatitis B Infection: A Review , 2018, JAMA.
[16] M. Buti,et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. , 2018, Journal of hepatology.
[17] B. McMahon,et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.
[18] John F. Flaherty,et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. , 2016, The lancet. Gastroenterology & hepatology.
[19] M. Kumar,et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.
[20] T. Brown,et al. Diagnosing and managing diabetes in HIV-infected patients: current concepts. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] V. Wong,et al. Hepatitis B virus infection and fatty liver in the general population. , 2012, Journal of hepatology.
[22] Sheng-Nan Lu,et al. Lower prevalence of hypercholesterolemia and hyperglyceridemia found in subjects with seropositivity for both Hepatitis B and C strains independently , 2010, Journal of gastroenterology and hepatology.
[23] Ming‐Lung Yu,et al. Viral Hepatitis Infections in Southern Taiwan: A Multicenter Community‐based Study , 2010, The Kaohsiung journal of medical sciences.
[24] C. Chu,et al. Hepatitis B virus infection , 2009, The Lancet.
[25] K. Samaras,et al. Antiretroviral therapy and the human immunodeficiency virus – improved survival but at what cost? , 2008, Diabetes, obesity & metabolism.
[26] K. Petersen,et al. Disordered lipid metabolism and the pathogenesis of insulin resistance. , 2007, Physiological reviews.
[27] Jianping Ye,et al. Serine Phosphorylation of Insulin Receptor Substrate 1 by Inhibitor κB Kinase Complex* 210 , 2002, The Journal of Biological Chemistry.
[28] I. G. Fantus,et al. Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-δ , 2002 .
[29] Roger Davis,et al. The c-Jun NH2-terminal Kinase Promotes Insulin Resistance during Association with Insulin Receptor Substrate-1 and Phosphorylation of Ser307 * , 2000, The Journal of Biological Chemistry.
[30] John F. Flaherty,et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. , 2016, The lancet. Gastroenterology & hepatology.